TUMOR IMMUNOLOGY 

Minerva Biotecnologica 1999 December;11(4):303-9

Copyright © 1999 EDIZIONI MINERVA MEDICA

language: English

Monoclonal antibodies for diagnosis and prognosis of human tumors

Ménard S.

Molecular Targeting Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy

Monoclonal anti­bod­ies (MAbs) ­that are reac­tive ­with ­tumor asso­ciat­ed anti­gens ­have led to ­many of the ­recent advanc­es ­made in ­tumor immu­nol­o­gy. At ­present, ­many of ­these MAbs ­have ­already ­been ­used in var­i­ous ­aspects of ­patient man­age­ment and in bet­ter under­stand­ing the biol­o­gy of car­ci­no­ma ­cell pop­u­la­tions. Because of ­their diver­sity, spec­i­fic­ity and bio­log­i­cal activ­ity, ­these MAbs are poten­tial­ly ­ideal ­reagents for a varie­ty of appli­ca­tions in malig­nant dis­or­ders ­such as clin­i­cal diag­no­sis ­using ser­um ­assays, immu­no­cy­to path­o­log­i­cal anal­y­ses of effu­sions or ­fine-nee­dle aspi­ra­tion spec­i­mens, bio­path­o­log­i­cal anal­y­sis of ­tumor spec­i­mens, immu­nos­cin­tig­ra­phy and radio­im­mu­no­guid­ed sur­gery.